The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors

Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients

(2019) Marie-Léa Gauci et al.   MELANOMA RESEARCH

Acquired Lipodystrophy Associated with Nivolumab in a Patient with Advanced Renal Cell Carcinoma

(2019) Camila Kruschewsky Falcao et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes

(2019) Alexandre Jehl et al.   DIABETES CARE

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

(2018) Angeliki M. Stamatouli et al.   DIABETES

Anti–Programmed Death 1 (PD-1) Antibodies and the Pancreas: A Diabetic Storm Ahead?

(2018) Lucien Marchand et al.   DIABETES CARE

Diabetes and Blood Glucose Disorders Under Anti-PD1

(2018) Quentin Magis et al.   JOURNAL OF IMMUNOTHERAPY

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab-induced fulminant type 1 diabetes (T1D): the first Italian case report with long follow-up and flash glucose monitoring

(2018) Francesco Tassone et al.   ACTA DIABETOLOGICA

Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype

(2018) Lucien Marchand et al.   ACTA DIABETOLOGICA

Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?

(2018) Lucien Marchand et al.   ACTA DIABETOLOGICA

Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes

(2018) Jordan J. Wright et al.   DIABETES CARE

Autoimmune pancreatitis after nivolumab anti–programmed death receptor-1 treatment

(2018) Lea Dehghani et al.   EUROPEAN JOURNAL OF CANCER

Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma

(2017) Matthew A Smith-Cohn et al.   Immunotherapy

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

(2017) Lucien Marchand et al.   Journal of Thoracic Oncology

PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes

(2017) Moufida Ben Nasr et al.   Science Translational Medicine

A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes

(2016) Young Kwang Chae et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy

(2016) Masahide Okamoto et al.   Journal of Diabetes Investigation

Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy

(2016) Jared R. Lowe et al.   Journal for ImmunoTherapy of Cancer

Low programmed cell death-1 (PD-1) expression in peripheral CD4+T cells in Japanese patients with autoimmune type 1 diabetes

(2015) R. Fujisawa et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The rise, fall, and resurgence of immunotherapy in type 1 diabetes

(2015) Moufida Ben Nasr et al.   PHARMACOLOGICAL RESEARCH

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data

(2012) C. J. Greenbaum et al.   DIABETES

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

(2011) Tihamer Orban et al.   LANCET